Biotron (ASX:BIT) has released new data demonstrating significant progress in its Hepatitis B Virus (HBV) development program, with its lead candidate BIT-HBV001 showing potent antiviral effects across multiple laboratory and animal models. …
Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity
November 15, 2025 Australian Biotech
Latest Video
New Stories
-
Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity
November 15, 2025 - - Australian Biotech -
Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose
November 15, 2025 - -
PYC reports sustained vision gains in RP11 clinical trial
November 15, 2025 - - Australian Biotech -
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
Prospection says data access and leadership are critical to unlock AI’s potential in healthcare
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments
November 14, 2025 - - Latest News